Next Century Growth Investors LLC Purchases 294,688 Shares of OptimizeRx Corp. $OPRX

Next Century Growth Investors LLC boosted its position in shares of OptimizeRx Corp. (NASDAQ:OPRX) by 139.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 505,407 shares of the company’s stock after acquiring an additional 294,688 shares during the period. Next Century Growth Investors LLC’s holdings in OptimizeRx were worth $6,196,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quantbot Technologies LP bought a new stake in OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets grew its stake in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue bought a new position in OptimizeRx in the fourth quarter valued at approximately $62,000. Worth Venture Partners LLC bought a new position in OptimizeRx in the third quarter valued at approximately $220,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in OptimizeRx in the fourth quarter valued at approximately $158,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Stock Performance

OptimizeRx stock opened at $5.23 on Monday. OptimizeRx Corp. has a 52 week low of $4.57 and a 52 week high of $22.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37. The stock has a market capitalization of $98.11 million, a P/E ratio of 14.94 and a beta of 1.13. The stock has a 50-day simple moving average of $5.84 and a 200 day simple moving average of $8.93.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.The business had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. Analysts expect that OptimizeRx Corp. will post 0.51 earnings per share for the current year.

OptimizeRx declared that its board has approved a share repurchase program on Thursday, March 5th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts have weighed in on OPRX shares. Roth Mkm decreased their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 6th. UBS Group set a $10.00 price target on OptimizeRx in a research note on Wednesday, May 13th. Lake Street Capital decreased their price target on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. B. Riley Financial decreased their price target on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, Stephens decreased their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.43.

OptimizeRx Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.